Jul, 2011
Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type
LEUKEMIA & LYMPHOMA
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- Volume
- 52
- Number
- 7
- First page
- 1255
- Last page
- 1261
- Language
- English
- Publishing type
- DOI
- 10.3109/10428194.2011.572322
- Publisher
- INFORMA HEALTHCARE
The prognosis for patients with advanced or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKL) is extremely poor. Thus, allogeneic stem cell transplantation (allo-HSCT) should be considered for this disease. However, reports of allo-HSCT for ENKL are limited because of the rarity of the disease. Here, we describe the clinical course of 12 cases of advanced and refractory ENKL treated with allo-HSCT, including five cases with cord blood transplant. With a median follow-up of 13 months (range, 1-168 months), seven patients are alive in remission, five have died, and one treatment-related death occurred. All patients with disease progression at transplant died of disease progression, whereas seven of eight patients with a complete or partial response are long-term survivors. Allo-HSCT is a feasible and promising consolidation therapy for advanced and relapsed ENKL. The disease status before allo-HSCT is well associated with general outcome, and thus induction treatment is very important for this disease.
- Link information
- ID information
-
- DOI : 10.3109/10428194.2011.572322
- ISSN : 1042-8194
- Web of Science ID : WOS:000291992400017